{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:30:07Z","timestamp":1794360607082,"version":"4.9.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec><jats:title>Background\/Purpose:<\/jats:title><jats:p>There is limited research regarding the consequences of treating lactating mothers with intravitreal anti\u2013vascular endothelial growth factor (VEGF) agents. Balancing the need for vision-saving treatment, the benefits of breastfeeding, and the concern for affecting the newborn can present a conflict for both mothers and ophthalmologists. This review summarizes the state of the literature regarding the use of intravitreal anti-VEGF agents during breastfeeding along with details about their pharmacology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Bevacizumab and aflibercept have Fc domains subjecting them to FcRn recycling and extending their half-life compared with ranibizumab which is an antibody fragment and lacks the Fc domain. Case reports and small studies have shown that ranibizumab has the lowest serum concentration after intravitreal injection and the least effect on plasma-free VEGF concentrations and breastmilk VEGF levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Clinical and pharmacologic data suggest that ranibizumab has less systemic circulation and effect on maternal serum and breastmilk VEGF levels when compared to bevacizumab and aflibercept. However, there is significant need for further research on the degree and duration to which intravitreal agents circulate systemically, what fraction is transferred into breastmilk and is absorbed, and whether this results in any functional adverse effects to the infant. Other factors to consider in the medical decision-making of lactating mothers necessitating intravitreal anti-VEGF treatment include the gestational and post-natal age of the child and whether it is feasible to avoid breastfeeding for the half-life duration of the intravitreal agent rather than ceasing breastfeeding altogether.<\/jats:p><\/jats:sec>","DOI":"10.1097\/iae.0000000000002946","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T01:05:18Z","timestamp":1597367118000},"page":"2065-2069","source":"Crossref","is-referenced-by-count":8,"title":["REVIEW OF OPHTHALMIC AND BREASTFEEDING MEDICINE EVIDENCE"],"prefix":"10.1097","volume":"40","author":[{"given":"Prarthana J.","family":"Dalal","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aloka L.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Rush University, Chicago, Illinois; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Carle","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alekya","family":"Rajanala","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjot K.","family":"Gill","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230817","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1097\/IAE.0000000000000517","article-title":"Bevacizumab levels in breast milk after long-term intravitreal injections","volume":"35","author":"McFarland","year":"2015","journal-title":"Retina"},{"key":"R2-20230817","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/bdrb.21026","article-title":"Embryo-fetal transfer of bevacizumab (Avastin) in the rat over the course of gestation and the impact of neonatal Fc receptor (FcRn) binding","volume":"95","author":"Thorn","year":"2012","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"R3-20230817","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1111\/j.1755-3768.2009.01572.x","article-title":"Early loss of pregnancy after intravitreal bevacizumab injection","volume":"88","author":"Petrou","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"R7-20230817","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3389\/fped.2018.00295","article-title":"Human milk: an ideal Food for nutrition of preterm newborn","volume":"6","author":"Boquien","year":"2018","journal-title":"Front Pediatr"},{"key":"R8-20230817","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1542\/peds.2011-3552","article-title":"Breastfeeding and the use of human milk","volume":"129","author":"Section on","year":"2012","journal-title":"Pediatrics"},{"key":"R9-20230817","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/ajcn\/72.5.1196","article-title":"Unbound vascular endothelial growth factor and its receptors in breast, human milk, and newborn intestine","volume":"72","author":"Vuorela","year":"2000","journal-title":"Am J Clin Nutr"},{"key":"R10-20230817","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1006\/cyto.2002.1032","article-title":"Human lactiferous mammary gland cells produce vascular endothelial growth factor (VEGF) and express the VEGF receptors, Flt-1 AND KDR\/Flk-1","volume":"18","author":"Nishimura","year":"2002","journal-title":"Cytokine"},{"key":"R11-20230817","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1203\/00006450-199905010-00007","article-title":"Vascular endothelial growth factor (VEGF) is present in human breast milk and its receptor is present on intestinal epithelial cells","volume":"45","author":"Siafakas","year":"1999","journal-title":"Pediatr Res"},{"key":"R12-20230817","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.siny.2018.08.008","article-title":"Intestinal microcirculation and necrotizing enterocolitis: the vascular endothelial growth factor system","volume":"23","author":"Bowker","year":"2018","journal-title":"Semin Fetal Neonatal Med"},{"key":"R13-20230817","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/pr.2017.219","article-title":"Dimethyloxalylglycine preserves the intestinal microvasculature and protects against intestinal injury in a neonatal mouse NEC model: role of VEGF signaling","volume":"83","author":"Bowker","year":"2018","journal-title":"Pediatr Res"},{"key":"R14-20230817","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R15-20230817","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1167\/iovs.12-10260","article-title":"Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach","volume":"54","author":"Xu","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R16-20230817","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2174\/187152811798104872","article-title":"Aflibercept (VEGF-TRAP): the next anti-VEGF drug","volume":"10","author":"Stewart","year":"2011","journal-title":"Inflamm Allergy Drug Targets"},{"key":"R17-20230817","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/j.1755-3768.2011.02240.x","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab","volume":"90","author":"Carneiro","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"R18-20230817","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/aos.12604","article-title":"Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial","volume":"93","author":"Zehetner","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"R19-20230817","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1001\/archophthalmol.2012.112","article-title":"Reduction of vascular endothelial growth factor a in human breast milk after intravitreal injection of bevacizumab but not ranibizumab","volume":"130","author":"Ehlken","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R20-20230817","first-page":"1069","article-title":"Transfer of single dose of intravitreal injection of ranibizumab and bevacizumab into milk of sheep","volume":"10","author":"Cakmak Argun","year":"2017","journal-title":"Int J Ophthalmol"},{"key":"R21-20230817","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ophtha.2019.08.022","article-title":"Ranibizumab and aflibercept levels in breast milk after intravitreal injection","volume":"127","author":"Juncal","year":"2020","journal-title":"Ophthalmology"},{"key":"R22-20230817","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/cpt.676","article-title":"Evaluation of the safety of drugs and biological products used during lactation: workshop summary","volume":"101","author":"Wang","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R23-20230817","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3748\/wjg.v16.i7.862","article-title":"Ontogeny, growth and development of the small intestine: understanding pediatric gastroenterology","volume":"16","author":"Drozdowski","year":"2010","journal-title":"World J Gastroenterol"},{"key":"R24-20230817","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jpeds.2017.01.013","article-title":"Intestinal barrier maturation in very low birthweight infants: relationship to feeding and antibiotic exposure","volume":"183","author":"Saleem","year":"2017","journal-title":"J Pediatr"},{"key":"R25-20230817","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R26-20230817","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.ophtha.2019.03.048","article-title":"Neurodevelopmental outcomes after intravitreal bevacizumab therapy for retinopathy of prematurity: a prospective case-control study","volume":"126","author":"Fan","year":"2019","journal-title":"Ophthalmology"},{"key":"R27-20230817","article-title":"Bevacizumab for retinopathy of prematurity: 2-year neurodevelopmental follow-up","author":"Zayek","year":"2020","journal-title":"Am J Perinatol"},{"key":"R28-20230817","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3928\/23258160-20200326-03","article-title":"Neurodevelopmental outcomes following intravitreal bevacizumab with laser versus laser photocoagulation alone for retinopathy of prematurity","volume":"51","author":"Ahmed","year":"2020","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R29-20230817","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41372-019-0420-z","article-title":"Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser","volume":"39","author":"Raghuram","year":"2019","journal-title":"J Perinatol"},{"key":"R30-20230817","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1016\/j.vaccine.2015.05.107","article-title":"The US FDA pregnancy lactation and labeling rule\u2014implications for maternal immunization","volume":"33","author":"Gruber","year":"2015","journal-title":"Vaccine"},{"key":"R31-20230817","first-page":"713","article-title":"The new pregnancy and lactation labeling rule","volume":"41","author":"Pernia","year":"2016","journal-title":"P T"},{"key":"R32-20230817","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","article-title":"Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans","volume":"146","author":"Krohne","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R33-20230817","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","article-title":"Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans","volume":"154","author":"Krohne","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R34-20230817","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.4081\/eye.2011.e5","article-title":"What are the half-lives of ranibizumab and aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical model","volume":"1","author":"Stewart","year":"2011","journal-title":"Eye Reports"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000002946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T20:01:18Z","timestamp":1723406478000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000002946"}},"subtitle":["Real and Theoretical Risks of Intravitreal Anti-Vascular Endothelial Growth Factor Administration in Lactating Women"],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000002946","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}